Candel Therapeutics, Inc.
CADL
$4.76
$0.224.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -27.01% | 98.02% | 49.09% | 60.55% | 66.15% |
| Gross Profit | 27.01% | -98.41% | -49.53% | -61.30% | -67.17% |
| SG&A Expenses | -0.06% | -1.12% | -6.66% | -6.98% | -0.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.13% | -2.89% | -2.74% | 2.28% | 9.06% |
| Operating Income | 14.13% | 2.81% | 2.58% | -2.55% | -9.45% |
| Income Before Tax | -45.44% | -63.49% | -55.34% | -39.87% | -101.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.44% | -63.49% | -55.34% | -39.87% | -101.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.44% | -63.49% | -55.34% | -39.87% | -101.87% |
| EBIT | 14.13% | 2.81% | 2.58% | -2.55% | -9.45% |
| EBITDA | 14.58% | 3.06% | 2.93% | -2.21% | -9.13% |
| EPS Basic | -33.80% | -57.70% | -52.76% | -39.34% | -101.35% |
| Normalized Basic EPS | -33.56% | -56.48% | -51.56% | -37.91% | -99.39% |
| EPS Diluted | -33.80% | -57.70% | -52.76% | -39.34% | -101.35% |
| Normalized Diluted EPS | -33.56% | -56.48% | -51.56% | -37.91% | -99.39% |
| Average Basic Shares Outstanding | 9.43% | 3.81% | 1.16% | 0.43% | 0.39% |
| Average Diluted Shares Outstanding | 9.43% | 3.81% | 1.16% | 0.43% | 0.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |